Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(162 products)
- Bcr-Abl(117 products)
- EGFR(594 products)
- FAK(72 products)
- FLT(90 products)
- Fibroblast Growth Factor Receptor (FGFR)(183 products)
- JAK(247 products)
- PDGFR(127 products)
- RAAS(90 products)
- Src(81 products)
- Syk(37 products)
- Thrombin(53 products)
- VDA(2 products)
- VEGFR(245 products)
Show 6 more subcategories
Found 2154 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR-IN-71
CAS:<p>EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.</p>Formula:C16H9ClIN3Color and Shape:SolidMolecular weight:405.62JAK-IN-26
CAS:JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency inFormula:C22H24N6O3Purity:98%Color and Shape:SolidMolecular weight:420.46EGFR/HER2-IN-11
CAS:EGFR/HER2-IN-11 (compound 20), an orally active dual inhibitor targeting human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), demonstrates IC50 values of 7.7 nM and 22 nM, respectively. This compound shows strong antitumor efficacy, specifically inhibiting the proliferation of BT-474 cancer cells with a GI50 of 601 nM [1].Formula:C23H21ClF3N5O2Molecular weight:491.89ALK/EGFR-IN-2
CAS:ALK/EGFR-IN-2 is a potent dual inhibitor targeting ALK and EGFR, promoting apoptosis and G0/G1 cell cycle arrest in cancer cells.Formula:C27H34ClN7O3SColor and Shape:SolidMolecular weight:572.12FGFR4-IN-8
CAS:FGFR4-IN-8 is a selective, ATP-competitive FGFR4 inhibitor with IC50s as low as 0.25 nM, halting growth of Hep3B cells at 29 nM and showing in vivo efficacy.Formula:C32H34Cl2FN7O3Purity:98%Color and Shape:SolidMolecular weight:654.56TIE-2/VEGFR-2 kinase-IN-5
CAS:TIE-2/VEGFR-2 kinase-IN-5 is a TIE-2 and VEGFR-2 tyrosine kinase receptor inhibitor commonly used in biomedical research related to angiogenesis.Formula:C21H13F6N5O2Purity:99.79%Color and Shape:SolidMolecular weight:481.35BMS-599626 Hydrochloride
CAS:BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.Formula:C27H28ClFN8O3Purity:99.98%Color and Shape:SolidMolecular weight:567.01Brolucizumab
CAS:Brolucizumab (anti-VEGF-A scFv) potently blocks VEGF-A to reduce neovascularization in wet AMD, with picomolar binding affinity.Purity:95%Color and Shape:LiquidEGFR-IN-74
EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.Formula:C32H28BrF3N6O4SColor and Shape:SolidMolecular weight:729.57Tyk2-IN-9
CAS:Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.Formula:C20H17N9Purity:98%Color and Shape:SolidMolecular weight:383.41Upadacitinib tartrate
CAS:Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.Formula:C21H33F3N6O11Purity:98%Color and Shape:SolidMolecular weight:602.521HDAC/JAK/BRD4-IN-1
CAS:HDAC/JAK/BRD4-IN-1 (compound 25ap) is a potent triple inhibitor targeting HDAC, JAK, and BRD4.Formula:C24H28N6O3Purity:98%Color and Shape:SolidMolecular weight:448.52N-desmethyl Regorafenib N-oxide
CAS:N-Desmethyl Regorafenib N-oxide, an active metabolite of the multi-kinase inhibitor regorafenib, originates through the action of the cytochrome P450 (CYP) isoform CYP3A4. This compound demonstrates efficacy in vitro by inhibiting key enzymes such as VEGFR2, Tie2, c-Kit, and B-RAF, and it exhibits tumor growth inhibition in HT-29 and MDA-MB-231 mouse xenograft models at a dosage of 1 mg/kg.Formula:C20H13ClF4N4O4Color and Shape:SolidMolecular weight:484.79BEBT-109
CAS:BEBT-109 is a selective epidermal growth factor receptor (EGFR) inhibitor that shows anti-tumor activity in EGFR-mutant non-small cell lung cancer.Formula:C27H32N8O3Purity:97.26%Color and Shape:SolidMolecular weight:516.6BT424
CAS:BT424, a specific HCK inhibitor, modulates macrophage activation and autophagy in vitro, and mitigates inflammation and renal fibrosis in the UUO model [1].Formula:C22H15BCl2N2O2Purity:98%Color and Shape:SolidMolecular weight:421.08CP-547632 TFA
CAS:CP-547632 TFA, an oral VEGFR-2 and FGF inhibitor, IC50: VEGFR-2 at 11 nM, FGF at 9 nM, shows antitumor activity.Formula:C22H25BrF5N5O5SPurity:98%Color and Shape:SolidMolecular weight:646.43PF-06459988
CAS:PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.Formula:C19H22ClN7O3Purity:98%Color and Shape:SolidMolecular weight:431.88EGFR/HER2-IN-13
CAS:EGFR/HER2-IN-13 (Compd 38) serves as an inhibitor targeting mutant EGFR/HER2s that show resistance to existing drugs. It is primarily utilized in cancer research.Formula:C27H36N8O3Molecular weight:520.63DZD1516
CAS:DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in bothFormula:C28H27F2N7O3Purity:98%Color and Shape:SolidMolecular weight:547.56PI3K/VEGFR2-IN-1
CAS:PI3K/VEGFR2-IN-1 is a potent dual inhibitor targeting both PI3K and VEGFR2 with IC50 values of 2.21 μM for PI3K and 68 μM for VEGFR2, respectively.Formula:C17H14ClN3OSPurity:98%Color and Shape:SolidMolecular weight:343.83
